BLSM
BlossomHill Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.21
−7.59%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -70.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -76.4%
- EBIT
- -75.9%
- Net income
- -97.3%
- EPS
- -96.2%
- Free cash flow
- -52.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026